Establishing tomorrow's standard of care

Debiopharm is an independent biopharmaceutical company based in Switzerland with an ongoing commitment to develop tomorrow’s standard of care to cure cancer & infectious diseases and improve patient quality of life. Our main activities include drug development, drug manufacturing and digital health investment.


Your task is not to foresee the future, but to enable it.
Antoine de St-Exupéry


For 40 years, we have been driven by the same commitment: bringing innovative solutions to patients

Our story began in 1979 when Dr. Rolland-Yves Mauvernay, convinced that many useful therapeutic products were abandoned before reaching their full potential, decided to establish Debiopharm, a company dedicated to in-licensing innovative compounds and developing them into medicines for out-licensing. Having launched this unique business model with a staff of only 2 people, today, Debiopharm’s 420 employees are now active in a variety of roles within drug development, drug manufacturing and investment in digital health and smart data start-ups.

Together with his son Thierry Mauvernay, they were able to build a team of dedicated professionals with a broad range of expertise. Debiopharm is now a group of three companies active in drug development (Debiopharm International), drug manufacturing (Debiopharm Research & Manufacturing) and digital health investment (Debiopharm Innovation Fund). Debiopharm is the Life Science division of our parent company Après-demain SA, active in asset diversification and philanthropy.

About Apres-demain
Corporate responsibility

Through corporate responsibility we aim to positively contribute to society and the environment

Learn more
Media Library

Find contact for media inquiries & download corporate resources

Awards and Grants

Each year Debiopharm co-organizes and presents two honors: the JCA-Mauvernay Award and the "Challenge Debiopharm-Inartis" Grant

Press releases

Latest Debiopharm's announcements for media and journalists

Press Releases